Does biomarker use in oncology improve clinical trial failure risk? A large‐scale analysis-Reference-Cited by-同舟云学术

Does biomarker use in oncology improve clinical trial failure risk? A large‐scale analysis

Published:2021-02-23 Issue:6 Volume:10 Page:1955-1963
ISSN:2045-7634
Container-title:Cancer Medicine
language:en
Short-container-title:Cancer Med

Author:

Parker Jayson L.¹^ORCID,Kuzulugil Sebnem S.²,Pereverzev Kirill¹,Mac Stephen³,Lopes Gilberto⁴,Shah Zain¹,Weerasinghe Ashini⁵,Rubinger Daniel¹,Falconi Adam⁶,Bener Ayse⁷,Caglayan Bora⁷,Tangri Rohan¹,Mitsakakis Nicholas⁸

Affiliation:

1. Department of Biology University of Toronto Mississauga Mississauga ON Canada

2. St Michael's Hospital Toronto ON Canada

3. Institute of Health Policy, Management and EvaluationUniversity of Toronto Mississauga ON Canada

4. University of MiamiMiller School of Medicine Coral Gables FL USA

5. Prevention and Cancer ControlCancer Care Ontario Toronto ON Canada

6. Department of Pharmacy Leslie Dan Faculty of Pharmacy University of Toronto Toronto ON Canada

7. Mechanical and Industrial Engineering Ryerson University Toronto ON Canada

8. Institute of Health Policy, Management and Evaluation, and Division of BiostatisticsDalla Lana School of Public HealthUniversity of Toronto Toronto ON Canada

Publisher

Wiley

Subject

Cancer Research,Radiology Nuclear Medicine and imaging,Oncology

Link

https://onlinelibrary.wiley.com/doi/pdf/10.1002/cam4.3732

Reference21 articles.

1. Biomarkers and Receptor Targeted Therapies Reduce Clinical Trial Risk in Non–Small-Cell Lung Cancer

2. Biomarker use is associated with reduced clinical trial failure risk in metastatic melanoma

3. Clinical Trial Risk in Non-Hodgkin’s Lymphoma: Endpoint and Target Selection

4. Clinical trial risk in castration-resistant prostate cancer: immunotherapies show promise

Cited by 22 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Development and validation of a novel combinational index of liquid biopsy biomarker for longitudinal lung cancer patient management;The Journal of Liquid Biopsy;2024-09

2. Network-driven cancer cell avatars for combination discovery and biomarker identification for DNA damage response inhibitors;npj Systems Biology and Applications;2024-06-21

3. Harnessing Immune Checkpoint Inhibitors Against Gastric Cancer: Charting the Course to Expanded Therapeutic Benefit;Biomedical Research and Therapy;2024-04-30

4. Utilization of fluid-based biomarkers as endpoints in disease-modifying clinical trials for Alzheimer’s disease: a systematic review;Alzheimer's Research & Therapy;2024-04-27

5. Translationale Forschung in der Onkologie: Hohe Präzision mit kombinierten Omics;Deutsches Ärzteblatt Online;2024-02-09